Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Dutasteride (02393220). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

DUTASTERIDE

All strengths: Limited Use — Reason for Use code 384, 385 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 384, 385 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (G04C, G04CB) — coverage varies; not interchangeable

  • Finasteride (Propecia): limited Use 384, 385, Not a benefit
  • Tamsulosin (Flomax CR Tab): general benefit, Not a benefit
  • Alfuzosin (Xatral): limited Use 351, 352
  • Silodosin (Rapaflo): limited Use 351, 352, Not a benefit

Apo-Dutasteride · DIN 02404206 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-18
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Dutasteride · DIN 02404206 Manufacturer: Apotex Inc.; listing date 2014-09-25 Health Canada: Marketed since 2014-07-18 · brand APO-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88899 · Verify on the e-Formulary ↗ (DIN 02404206)

Source record
DIN 02404206: Apo-Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id APX Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404206 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88899
Interchangeable products
Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended 2024-06-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404206
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Dutasteride · DIN 02469308 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Dutasteride · DIN 02469308 Manufacturer: Auro Pharma Inc.; listing date 2018-07-31 Health Canada: Marketed since 2018-06-04 · brand AURO-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95804 · Verify on the e-Formulary ↗ (DIN 02469308)

Source record
DIN 02469308: Auro-Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id AUR Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469308 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95804
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended 2024-06-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02469308
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Avodart · DIN 02247813 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-19
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Avodart (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Avodart · DIN 02247813 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2005-09-27 Health Canada: Marketed since 2003-11-14 · brand AVODART · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72107 · Verify on the e-Formulary ↗ (DIN 02247813)

Source record
DIN 02247813: Avodart Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id GSK Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.2717; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247813 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72107
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247813
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dutasteride · DIN 02429012 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Dutasteride · DIN 02429012 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2026-07-14 · brand DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91345 · Verify on the e-Formulary ↗ (DIN 02429012)

Source record
DIN 02429012: Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id SIV Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429012 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91345
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended 2026-07-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02429012
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dutasteride · DIN 02443058 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Dutasteride · DIN 02443058 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Marketed since 2026-01-21 · brand DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92760 · Verify on the e-Formulary ↗ (DIN 02443058)

Source record
DIN 02443058: Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id SAI Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443058 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92760
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended 2026-05-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443058
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Dutasteride Capsules · DIN 02546167 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Dutasteride Capsules · DIN 02546167 Manufacturer: Jamp Pharma Corporation; listing date 2025-05-30 Health Canada: Marketed since 2025-03-17 · brand JAMP DUTASTERIDE CAPSULES · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Dutasteride Capsules: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103488 · Verify on the e-Formulary ↗ (DIN 02546167)

Source record
DIN 02546167: Jamp Dutasteride Capsules Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id JPC Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02546167 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103488
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02546167
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Dutasteride · DIN 02428873 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-19
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Dutasteride · DIN 02428873 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-11-27 Health Canada: Marketed since 2014-09-19 · brand MINT-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91334 · Verify on the e-Formulary ↗ (DIN 02428873)

Source record
DIN 02428873: Mint-Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id MIN Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428873 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91334
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended 2018-02-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428873
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Priva-Dutasteride · DIN 02490587 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-19
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Priva-Dutasteride · DIN 02490587 Manufacturer: Pharmapar Inc.; listing date 2021-05-31 Health Canada: Marketed since 2024-01-02 · brand NRA-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Priva-Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98062 · Verify on the e-Formulary ↗ (DIN 02490587)

Source record
DIN 02490587: Priva-Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id PHP Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490587 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98062
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02490587
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Dutasteride · DIN 02424444 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-02
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Dutasteride · DIN 02424444 Manufacturer: Sandoz Canada Inc.; listing date 2014-09-25 Health Canada: Marketed since 2024-06-17 · brand SANDOZ DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90912 · Verify on the e-Formulary ↗ (DIN 02424444)

Source record
DIN 02424444: Sandoz Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id SDZ Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02424444 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90912
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended 2026-04-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02424444
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Dutasteride · DIN 02408287 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredMarketed · checked 2026-09-18
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Dutasteride · DIN 02408287 Manufacturer: Teva Canada Limited; listing date 2014-09-25 Health Canada: Marketed since 2014-07-16 · brand TEVA-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89301 · Verify on the e-Formulary ↗ (DIN 02408287)

Source record
DIN 02408287: Teva-Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id TEV Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408287 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89301
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565
Shortage status: resolved shortage (ended 2026-04-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02408287
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Dutasteride · DIN 02484870 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredDormant since 2026-08-03 · checked 2026-09-02 · What does dormant mean?
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Dutasteride · DIN 02484870 Manufacturer: Jamp Pharma Corporation; listing date 2020-01-31 Health Canada: Dormant since 2026-08-03 · brand JAMP DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97515 · Verify on the e-Formulary ↗ (DIN 02484870)

Source record
DIN 02484870: Jamp Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id JPC Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02484870 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97515
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Med-Dutasteride · DIN 02416298 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended 2025-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02484870
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-08-03 — choose a marketed DIN from the same-category list.

Med-Dutasteride · DIN 02416298 · 0.5mg · capsule

Limited Use — Reason for Use code 384, 385 requiredDormant since 2026-07-22 · checked 2026-09-19
Write on scriptLU code 384, 385 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 384, 385
Reason for Use code 384 For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 385 For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. Coverage limit: * Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Dutasteride · DIN 02416298 Manufacturer: Generic Medical Partners Inc.; listing date 2014-12-18 Health Canada: Dormant since 2026-07-22 · brand MED-DUTASTERIDE · ATC G04CB02 DUTASTERIDE · form Capsule · route Oral · ingredients DUTASTERIDE 0.5 MG · company Generic medical partners inc · schedule Prescription
Check this DIN again · Health Canada product record

Med-Dutasteride: Formulary list price $0.2565/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2565 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90086 · Verify on the e-Formulary ↗ (DIN 02416298)

Source record
DIN 02416298: Med-Dutasteride Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000524; group id 911; item number 2184; lccId 00166; manufacturer id GMP Source form: Cap; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2565; ministry $0.2565 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02416298 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90086
Interchangeable products
Apo-Dutasteride · DIN 02404206 · $0.2565 Auro-Dutasteride · DIN 02469308 · $0.2565 Avodart · DIN 02247813 · $0.2565 Dutasteride · DIN 02429012 · $0.2565 Dutasteride · DIN 02443058 · $0.2565 Jamp Dutasteride · DIN 02484870 · $0.2565 Jamp Dutasteride Capsules · DIN 02546167 · $0.2565 Mint-Dutasteride · DIN 02428873 · $0.2565 Priva-Dutasteride · DIN 02490587 · $0.2565 Sandoz Dutasteride · DIN 02424444 · $0.2565 Teva-Dutasteride · DIN 02408287 · $0.2565
Shortage status: resolved shortage (ended 2022-09-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416298
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-22 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

FINASTERIDE

· 23 products · Off-Formulary Interchangeable, not an ODB benefit (8), Limited Use, codes 384, 385 (15) · strengths: 1mg, 5mg · Tab

TAMSULOSIN HCL

· 10 products · General benefit (9), Listed, not a benefit (1) · strengths: 0.4mg · ER Cap

ALFUZOSIN HYDROCHLORIDE

· 6 products · Limited Use, codes 351, 352 · strengths: 10mg · Prolong-Rel Tab

SILODOSIN

· 10 products · Listed, not a benefit (2), Limited Use, codes 351, 352 (8) · strengths: 4mg, 8mg · Cap

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications Monotherapy: AVODART (dutasteride) is indicated for the treatment of symptomatic Benign Prostatic Hyperplasia (BPH) in men with enlarged prostates. Combination therapy: AVODART (dutasteride) in combination with the alpha blocker, tamsulosin, is indicated for the treatment of moderate to severe symptomatic BPH in men with enlarged prostates. AVODART administered alone or in combination with the alpha blocker, tamsulosin, has been shown to reduce prostate size, improve urinary flow and symptoms of BPH. AVODART administered as monotherapy has been shown to reduce the risk of acute urinary retention (AUR) and the need for BPH related surgery. Combination therapy was statistically significant to tamsulosin monotherapy but not dutasteride monotherapy at reducing the relative risk of AUR or BPH- related surgery (see 14 Clinical Trials). Limitations of Use: AVODART is not approved for the prevention of prostate cancer. 1.1. Pediatrics BPH is not a disease of childhood. AVODART is contraindicated for use in children. Safety and effectiveness in children have not been established. 1.2. Geriatrics Of 2,167 men treated with dutasteride in the 3 pivotal studies, 60% were age 65… https://pdf.hres.ca/dpd_pm/00085747.PDF PM date: 2026-08-12 Source product: AVODART; DIN 02247813; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)